Search

everythinglearnresearchcommunity

for

Search:↓

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Activating PKCα in skin causes cell death and inflammation through different pathways.

Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Restoring hair bulb immune privilege is crucial for managing alopecia areata.

Alopecia areata treatment varies, with no optimal method established yet.

NF-κB is crucial for zebrafish heart repair, affecting heart cell growth and repair processes.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Costunolide may have multiple health benefits, including promoting hair growth and protecting against cancer and diabetes, but more research is needed.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

Blocking IL-17 signaling may reduce skin inflammation and delay aging.

There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.

Understanding how hair follicle stem cells work can help find new ways to prevent hair loss and promote hair growth.

The document concludes that the skin's immune system is complex, involving interactions with hair follicles, nerves, and microbes, and can protect or cause disease, offering targets for new treatments.

The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Small molecule drugs show promise for advancing regenerative medicine but still face development challenges.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.